IXI
iShares Global Consumer Staples ETF
🇦🇺 ASX
🌏 GLOBAL
👑 Overview
📈 Performance
📙 Holdings
💰 Distributions
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 3.33%
Annual Growth
5 years average annual growth
💰
2.02%
Annual distribution yield
Based on the most recent distribution
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
38
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
IXI.AX was created on 2006-09-12 by iShares. The fund's investment portfolio concentrates primarily on consumer staples equity. The fund aims to provide investors with the performance of the S&P Global 1200 Consumer Staples Sector Index, before fees and expenses. The index is designed to measure the performance of global consumer staples companies and may include large-, mid- or smallcapitalisation stocks.
📈 Performance
Price History
+63.51%
1M
1Y
10Y
Graph
Table
How could long term investing grow your wealth?*
Based on an initial investment of
$
and recurring investments every
for
$
Your wealth could grow to...
$66,960.36
after 5 years
$144,268.62
after 10 years
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →📙 Top Holdings
Show more
Updated as of 17 January 2025
Industry Exposure
📙 Other
100%
Country Exposure
🇺🇸 United States
62%
🇬🇧 United Kingdom of Great Britain and Northern Ireland
12%
🇯🇵 Japan
6%
🇨🇭 Switzerland
5%
🇫🇷 France
4%
🇨🇦 Canada
2%
🇳🇱 Netherlands
2%
🇧🇪 Belgium
2%
🇦🇺 Australia
1%
🇲🇽 Mexico
1%
🇩🇪 Germany
1%
💰 Distributions
Payouts
💰 Annual Distribution Yield*
2.02%
💰 Annual Distribution Earnings Per $1,000 invested**
$20.23
💰 Most Recent Distribution Franked Percentage Estimate
0.00%
💰 Average Distribution Franked Percentage Estimate
0.00 %
💰 Distribution reinvestment
* Based on the most recent distribution
** Calculated by multiplying the most recent distribution yield by $1,000
Estimate your distribution
If you held
$
of IXI, your last distribution payment(s) would have been:
$ 115.67
on Thu Jan 09 2025
$ 91.52
on Thu Jul 11 2024
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Distribution History
1Y
5Y
10Y
Graph
Table
Year
Yearly Distribution Earnings Per Share
Franking Estimate
2025
$0.00
0.00%
2024
$2.34
0.00%
2023
$1.80
0.00%
2022
$1.73
0.00%
2021
$1.71
0.00%
2020
$1.58
0.00%
2019
$1.61
0.00%
2018
$1.97
0.00%
2017
$2.45
0.00%
2016
$2.35
0.00%
💵 Costs
💼
0.40%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$97.41
💰 Price To Earnings Ratio
0.00
💰 Price To Book Ratio
0.00
💰 Leveraged
No
💰 Inverse
No
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in IXI
38
📊 Total Capital Earnings
$87K
🔃 Average investment frequency
27 weeks
💵 Average investment amount
$2,736
⏰ Last time a customer invested in IXI
12 days
IXI investor breakdown
💵 Income of investors
More than 200k
8%
150k - 200k
13%
100k - 150k
23%
50k - 100k
13%
Less than 50k
38%
👶 Age of investors
18 - 25
26 - 34
21%
35 - 90
74%
🙋 Legal gender of investors
Female
34%
Male
66%
Pearlers who invest in IXI also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.17%
📊 Share price
$102.68 AUD
🧱 MATERIALS
⛳️ DIVERSIFIED
💸 FINANCIALS
🇦🇺 AUSTRALIA
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
18.18%
📊 Share price
$63.70 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
12.88%
📊 Share price
$142.08 AUD
🤖 TECHNOLOGY
🌏 GLOBAL
📈 HIGH PRICE GROWTH
⛳️ DIVERSIFIED
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
🙌 Performance (5Yr p.a)
23.00%
📊 Share price
$51.24 AUD
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
🇺🇸 UNITED STATES
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.37%
📊 Share price
$69.61 AUD
⛳️ DIVERSIFIED
🌏 GLOBAL
Want more shares? Try these...
IXJ.AX was created on 2001-11-13 by iShares. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of global biotechnology, healthcare, medical equipment and pharmaceuticals companies and may include large-, mid- or smallcapitalisation stocks
🙌 Performance (5Yr p.a)
7.25%
📊 Share price
$142.67 AUD
🇺🇸 UNITED STATES
Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Perth, Western Australia. The company went IPO on 2019-07-05. The firm is focused on focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP) including traumatic brain injury (TBI), stroke and hydrocephalus. In addition, the Company has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Presendin is the Company’s filed (and granted) trademark name for reformulated Exenatide. The firm is focused on managing the close out of the Phase III Idiopathic Intracranial Hypertension (IIH) EVOLVE clinical trial and explore new potential applications for Exenatide in TBI and other neurological disorders with raised ICP, consistent with its patents.
🙌 Performance (5Yr p.a)
-18.84%
📊 Share price
$0.07 AUD
📦 LOGISTICS